L'intérêt à découvert pour Insmed donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Insmed. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Insmed (NASDAQ:INSM) Stock, Rapport sur les intérêts à découvert

Insmed

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Insmed Inc

RBC Capital Markets has initiated coverage on Insmed Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), citing brensocatib&#8217;s launch momentum.
In February, the FDA accepted the company&#8217;s New Drug Application (NDA) for brensocatib for patients with bronchiectasis and granted the application Priority Review with a Prescription Drug User Fee Act target action date of&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43843781/insmed-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-business-update" rel="noreferrer noopener">August 12, 2025</a>.
If approved, Insmed expects brensocatib to launch in the U.S. in the third quarter.
The FDA also informed the company that it does not currently plan to hold an advisory committee meeting to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43910133/insmed-announces-that-fda-does-not-currently-plan-to-hold-advisory-committee-meeting-to-discuss-ne" rel="noreferrer noopener">discuss the New Drug Application</a>.
RBC Capital analyst Leonid Timashev says brensocatib has potential for a $6.5 billion opportunity in bronchiectasis and a rapid launch, &#8220;making Insmed an attractive midcap biotech.&#8221;
RBC has initiated with an Outperform rating with a <a target="_blank" href="https://www.benzinga.com/quote/INSM/analyst-ratings" rel="noreferrer noopener">price forecast of $100</a>.
The RBC analyst expects a high likelihood of approval for the bronchiectasis treatment with a favorable label, paving the way for a strong launch. Feedback from key opinion leaders (KOLs) and the company&#8217;s prelaunch efforts and education suggests a strong willingness to prescribe. Around 50% or more of eligible patients could receive brensocatib after its mid-2025 launch.
While insurance coverage and reaching moderate patients may pose early challenges, frequent patient visits, positive initial experiences, and being the only approved treatment should drive adoption and coverage. Past respiratory drug launches (asthma, COPD) have performed well.
RBC says Arikayce, an antibiotic, continues to generate steady revenue and has strong potential for a major label expansion if the Phase 3 ENCORE study delivers positive results in 2026. Leonid Timashev estimates peak sales could reach $1 billion, valuing Arikayce at up to $25 per share.
Last week, Insmed reported a fourth-quarter loss of $1.32 per share, missing the consensus loss of $1.17. Sales reached $104.4 million, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $101.79 million</a>.
Insmed anticipates full-year 2025 global Arikayce revenue of $405 million-$425 million, up 11%-17% year over year.
Price Action: INSM stock closed down by 3.17% to $77.49 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43945751/huawei-boosts-ai-chip-production-despite-taiwan-semi-and-asml-ban-aims-to-challenge-nvidia-in-china" target="_blank" rel="noreferrer noopener">Huawei Boosts AI Chip Production Despite Taiwan Semi And ASML Ban, Aims to Challenge Nvidia In China</a></li>
</ul>
Image via Shutterstock

Analyst Color

Biotech

News

Health Care

Initiation

Analyst Ratings

Movers

Trading Ideas

General

INSM

Lung Disease-Focused Insmed 'Is An Attractive Midcap Biotech,' Analyst Says

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Jefferies analyst Roger Song initiated coverage on Wave Life Sciences Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Buy rating and announced a price target of $26. WAVE Life Sciences shares closed at $10.48 on Monday. <a href="https://www.benzinga.com/quote/WVE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>TD Securities analyst Andrew Charles initiated coverage on Kura Sushi USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRUS#NASDAQ">KRUS</a>) with a Hold rating and announced a price target of $72. Kura Sushi USA shares closed at $64.71 on Monday. <a href="https://www.benzinga.com/quote/KRUS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners analyst Joseph Schwartz initiated coverage on Maze Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) with an Outperform rating and announced a price target of $28. Maze Therapeutics shares closed at $10.82 on Monday. <a href="https://www.benzinga.com/quote/MAZE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital analyst Leonid Timashev initiated coverage on Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with an Outperform rating and announced a price target of $100. Insmed shares closed at $80.03 on Monday. <a href="https://www.benzinga.com/quote/INSM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Tim Rezvan initiated coverage on Infinity Natural Resources, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INR#NYSE">INR</a>) with an Overweight rating and announced a price target of $26. Infinity shares closed at $19.13 on Monday. <a href="https://www.benzinga.com/quote/INR/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying INSM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25132813/image-204-1024x583.png" alt="" class="wp-image-798137" style="width:585px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25132813/image-204-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25132813/image-204-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25132813/image-204-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25132813/image-204.png 1142w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/25/02/43937701/how-to-earn-500-a-month-from-lowes-stock-ahead-of-q4-earnings"> </a>
<ul>
<li><a href="https://www.benzinga.com/25/02/43937701/how-to-earn-500-a-month-from-lowes-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Lowe&#8217;s Stock Ahead Of Q4 Earnings</a></li>
</ul>

Markets

Morgan Stanley Market Vectors Rupee/USD ETN

KRUS

MAZE

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

RBC Capital analyst Leonid Timashev initiates coverage on Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Outperform rating and announces Price Target of $100.

Price Target

RBC Capital Initiates Coverage On Insmed with Outperform Rating, Announces Price Target of $100

Guggenheim analyst Vamil Divan reiterates Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and maintains $101 price target.

Reiteration

Guggenheim Reiterates Buy on Insmed, Maintains $101 Price Target

Insmed Announces FDA No Advisory Meeting For Brensocatib NDA In Non-Cystic Fibrosis Bronchiectasis

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and maintains $90 price target.

HC Wainwright & Co. Reiterates Buy on Insmed, Maintains $90 Price Target

Truist Securities analyst Nicole Germino maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and raises the price target from $105 to $108.

Truist Securities Maintains Buy on Insmed, Raises Price Target to $108

Stifel analyst Stephen Willey maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and lowers the price target from $97 to $96.

Stifel Maintains Buy on Insmed, Lowers Price Target to $96

Cantor Fitzgerald analyst Jennifer Kim reiterates Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) from Overweight to Overweight.

Cantor Fitzgerald Reiterates Overweight on Insmedto Overweight

Insmed shares are trading lower after the company reported Q4 financial results and missed its EPS estimate.

As of December 31, 2024, Insmed had cash, cash equivalents, and marketable securities totaling approximately $1.4 billion.
The Company plans to continue to invest in the following key activities in 2025:
<ul>
<li>Commercialization and expansion of ARIKAYCE globally.</li>
<li>Commercial launch of brensocatib in the U.S., if approved, with advancement of regulatory submissions in the EU, UK, and Japan.</li>
<li>Advancement of clinical trial programs for brensocatib, including the ongoing Phase 2b BiRCh study in patients with CRSsNP and the Phase 2b CEDAR study in patients with HS.</li>
<li>Advancement of the clinical trial program for ARIKAYCE, which is intended to satisfy the post-marketing requirement for full approval of its current indication and potentially support label expansion to include all patients with a MAC lung infection.</li>
<li>Advancement of the clinical development programs for TPIP, including the Phase 2b study in patients with PAH and the initiation of a Phase 3 study in patients with PH-ILD.</li>
<li>Advancement of the clinical trial program for INS1201 in DMD.</li>
<li>Continued development of its pre-clinical research programs</li>
</ul>

Earnings

Guidance

Insmed Continues To Anticipate Full-year 2025 Global Arikayce Revenues In The Range Of $405M-$425M, Representing Between 11% And 17% Year-over-year Growth Compared To 2024

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(1.17) by 12.82 percent. This is a 3.13 percent decrease over losses of $(1.28) per share from the same period last year. The company reported quarterly sales of $104.44 million which beat the analyst consensus estimate of $101.79 million by 2.60 percent. This is a 24.79 percent increase over sales of $83.69 million the same period last year.

Insmed Q4 2024 GAAP EPS $(1.32) Misses $(1.17) Estimate, Sales $104.44M Beat $101.79M Estimate

ACCO

AKAM

ALIT

ALRM

ARDX

ATHM

AXTI

BABA

BAND

BBDC

BBIO

BIGC

BILI

BIRK

BJRI

BKNG

BLDR

CARG

CCRD

CDRO

CELH

CENX

CERS

CGAU

COKE

COLD

CPRT

CRAI

CSTM

DAVA

DBRG

DGICA

DGICB

DINO

DVAX

EPAM

ESAB

EXPI

FIVN

FRPT

FYBR

GDYN

GKOS

GLOB

GLPI

GMED

GRAL

INDI

INDV

INOD

IRTC

ITGR

Earnings Scheduled For February 20, 2025

Wells Fargo analyst Tiago Fauth maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Overweight and raises the price target from $85 to $107.

Wells Fargo Maintains Overweight on Insmed, Raises Price Target to $107

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 10 years by 4.85% on an annualized basis producing an average annual return of 16.1%. Currently, Insmed has a market capitalization of $14.02 billion. 
Buying $100 In INSM: If an investor had bought $100 of INSM stock 10 years ago, it would be worth $440.03 today based on a price of $78.37 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739551507_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today

Insmed's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NYSE">INSM</a>) short percent of float has fallen 3.63% since its last report. The company recently reported that it has 14.54 million shares sold short, which is 8.23% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.75 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Insmed Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739545211_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Insmed has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Insmed's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Insmed's peer group average for short interest as a percentage of float is 5.00%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Insmed's Recent Short Interest

Ratings for Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Insmed, revealing an average target of $92.6, a high estimate of $101.00, and a low estimate of $83.00. Surpassing the previous average price target of $85.00, the current average has increased by 8.94%.
<img src="https://www.benzinga.com/files/images/story/2025/1739300419_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Insmed. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$97.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$101.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$83.00</td>
<td>$74.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Insmed. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Insmed compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Insmed's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/INSM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Insmed analyst ratings.</a>
<h2>Unveiling the Story Behind Insmed</h2>
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
<h3>Unraveling the Financial Story of Insmed</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Insmed's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 18.15%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -236.04%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Insmed's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -84.45%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Insmed's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -11.42%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Insmed's debt-to-equity ratio is below the industry average. With a ratio of 2.07, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insmed Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

Stifel analyst Stephen Willey maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and raises the price target from $88 to $97.

Stifel Maintains Buy on Insmed, Raises Price Target to $97

Offerings

Press Releases

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Insmed Provides Business Update at 43rd Annual J.P. Morgan Healthcare Conference

FDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025

Insmed to Host Fourth-Quarter and Full-Year 2024 Financial Results Conference Call on Thursday, February 20, 2025

Insmed To Present at March 2025 Investor Conferences

Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update

Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis

Comments

Insmed

Intérêt court

Insmed (NASDAQ:INSM) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL